IRIS Accounts Production v24.2.0.383 07609132 director 1.1.23 31.12.23 31.12.23 0 0 true false true false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh076091322022-12-31076091322023-12-31076091322023-01-012023-12-31076091322021-12-31076091322022-01-012022-12-31076091322022-12-3107609132ns15:EnglandWales2023-01-012023-12-3107609132ns14:PoundSterling2023-01-012023-12-3107609132ns10:Director12023-01-012023-12-3107609132ns10:PrivateLimitedCompanyLtd2023-01-012023-12-3107609132ns10:SmallEntities2023-01-012023-12-3107609132ns10:AuditExemptWithAccountantsReport2023-01-012023-12-3107609132ns10:SmallCompaniesRegimeForDirectorsReport2023-01-012023-12-3107609132ns10:SmallCompaniesRegimeForAccounts2023-01-012023-12-3107609132ns10:FullAccounts2023-01-012023-12-3107609132ns10:RegisteredOffice2023-01-012023-12-3107609132ns5:CurrentFinancialInstruments2023-12-3107609132ns5:CurrentFinancialInstruments2022-12-3107609132ns5:ShareCapital2023-12-3107609132ns5:ShareCapital2022-12-3107609132ns5:RetainedEarningsAccumulatedLosses2023-12-3107609132ns5:RetainedEarningsAccumulatedLosses2022-12-3107609132ns5:ComputerEquipment2023-01-012023-12-3107609132ns5:ComputerEquipment2022-12-3107609132ns5:ComputerEquipment2023-12-3107609132ns5:ComputerEquipment2022-12-3107609132ns5:Subsidiary12023-01-012023-12-31076091321ns5:Subsidiary12023-01-012023-12-3107609132ns5:Subsidiary12023-12-3107609132ns5:Subsidiary12022-12-3107609132ns5:Subsidiary12022-01-012022-12-3107609132ns5:Subsidiary32023-01-012023-12-31076091325ns5:Subsidiary32023-01-012023-12-3107609132ns5:Subsidiary32023-12-3107609132ns5:Subsidiary32022-12-3107609132ns5:Subsidiary32022-01-012022-12-3107609132ns5:WithinOneYearns5:CurrentFinancialInstruments2023-12-3107609132ns5:WithinOneYearns5:CurrentFinancialInstruments2022-12-31
REGISTERED NUMBER: 07609132 (England and Wales)















UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2023

FOR

PHARMA-X CONSULTANCY LTD

PHARMA-X CONSULTANCY LTD (REGISTERED NUMBER: 07609132)






CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 3

Chartered Accountants' Report 5

PHARMA-X CONSULTANCY LTD

COMPANY INFORMATION
FOR THE YEAR ENDED 31 DECEMBER 2023







DIRECTOR: H I Dhanraj





REGISTERED OFFICE: 29 Filsham Road
St Leonards on Sea
East Sussex
TN38 0PA





REGISTERED NUMBER: 07609132 (England and Wales)





ACCOUNTANTS: Ashdown Hurrey
Chartered Accountants & Business Advisers
20 Havelock Road
Hastings
East Sussex
TN34 1BP

PHARMA-X CONSULTANCY LTD (REGISTERED NUMBER: 07609132)

BALANCE SHEET
31 DECEMBER 2023

31.12.23 31.12.22
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 780 975
Investments 5 - -
780 975

CURRENT ASSETS
Debtors 6 12,356 8,000
Investments 7 48,496 48,496
Cash at bank 5,853 3,724
66,705 60,220
CREDITORS
Amounts falling due within one year 8 53,031 55,644
NET CURRENT ASSETS 13,674 4,576
TOTAL ASSETS LESS CURRENT
LIABILITIES

14,454

5,551

PROVISIONS FOR LIABILITIES 148 185
NET ASSETS 14,306 5,366

CAPITAL AND RESERVES
Called up share capital 100 100
Retained earnings 14,206 5,266
SHAREHOLDERS' FUNDS 14,306 5,366

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2023.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2023 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 19 September 2024 and were signed by:




H I Dhanraj - Director


PHARMA-X CONSULTANCY LTD (REGISTERED NUMBER: 07609132)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

1. STATUTORY INFORMATION

Pharma-X Consultancy Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
In preparing the financial statements, the director is required to make an assessment of the ability of the company to continue as a going concern. The director has considered all available evidence for the company which covers the 12 month period from the date of signing these financial statements

On the basis of this consideration, the director is confident that the company has adequate resources to continue in operational existence and to meet its liabilities as they fall due for the foreseeable future. In reaching this conclusion he is satisfied that no material uncertainty exists. As a result of the above, the director has concluded that it remains appropriate to adopt a going concern basis of preparation in these financial statements and that no material uncertainty exists in reaching this conclusion.

Turnover
Turnover represents net invoiced sale of services, excluding value added tax, and is recognised upon completion of the services.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Computer equipment - 20% on reducing balance

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was NIL (2022 - NIL).

4. TANGIBLE FIXED ASSETS
Computer
equipment
£   
COST
At 1 January 2023
and 31 December 2023 2,665
DEPRECIATION
At 1 January 2023 1,690
Charge for year 195
At 31 December 2023 1,885
NET BOOK VALUE
At 31 December 2023 780
At 31 December 2022 975

PHARMA-X CONSULTANCY LTD (REGISTERED NUMBER: 07609132)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2023

5. FIXED ASSET INVESTMENTS

The company's investments at the Balance Sheet date in the share capital of companies include the following:

Pharma-X Consultancy Inc 8019 Guyana
Registered office: 34 Garnett Street, Newtown Kitty, Georgetown, Guyana
Nature of business: Trading in pharmaceutical supplies
%
Class of shares: holding
Ordinary 100.00
31.12.23 31.12.22
£    £   
Aggregate capital and reserves 80 80
Profit/(loss) for the year 1,207 (23,218 )

Interface Pharma Inc 42826 Barbados
Registered office: The Grove, 21 Pine Road, Belleville, St Michael, Barbados
Nature of business: Trading in pharmaceutical supplies
%
Class of shares: holding
Common 100.00
31.12.23 31.12.22
£    £   
Aggregate capital and reserves 81,953 57,558
Profit for the year 14,994 24,790

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.12.23 31.12.22
£    £   
Trade debtors 4,356 -
Interface Pharma Inc 8,000 8,000
12,356 8,000

7. CURRENT ASSET INVESTMENTS
31.12.23 31.12.22
£    £   
Shares in Pharma-X Consultancy
Inc 80 80
Shares in Interface Pharma Inc 48,416 48,416
48,496 48,496

8. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.12.23 31.12.22
£    £   
Tax 1,711 -
Other creditors 48,416 48,416
Directors' current accounts 2,182 6,507
Accrued expenses 722 721
53,031 55,644

9. RELATED PARTY DISCLOSURES

At the period end, H I Dhanraj, who is director, was owed £2,182 (2021 :£6,507) from the company. There are no terms attached to this loan.

CHARTERED ACCOUNTANTS' REPORT TO THE DIRECTOR
ON THE UNAUDITED FINANCIAL STATEMENTS OF
PHARMA-X CONSULTANCY LTD

The following reproduces the text of the report prepared for the director in respect of the company's annual unaudited financial statements. In accordance with the Companies Act 2006, the company is only required to file a Balance Sheet. Readers are cautioned that the Income Statement and certain other primary statements and the Report of the Director are not required to be filed with the Registrar of Companies.

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of Pharma-X Consultancy Ltd for the year ended 31 December 2023 which comprise the Income Statement, Balance Sheet and the related notes from the company's accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed within the ICAEW's regulations and guidance at http://www.icaew.com/en/membership/regulations-standards-and-guidance.

This report is made solely to the director of Pharma-X Consultancy Ltd in accordance with our terms of engagement. Our work has been undertaken solely to prepare for your approval the financial statements of Pharma-X Consultancy Ltd and state those matters that we have agreed to state to the director of Pharma-X Consultancy Ltd in this report in accordance with ICAEW Technical Release 07/16AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Pharma-X Consultancy Ltd and its director for our work or for this report.

It is your duty to ensure that Pharma-X Consultancy Ltd has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and profit of Pharma-X Consultancy Ltd. You consider that Pharma-X Consultancy Ltd is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the financial statements of Pharma-X Consultancy Ltd. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.






Ashdown Hurrey
Chartered Accountants & Business Advisers
20 Havelock Road
Hastings
East Sussex
TN34 1BP


20 September 2024